A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Phase 1/2 Withdrawn
CheckCell-2
Phase 1/2 Withdrawn
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
Phase 1/2 Withdrawn
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Phase 1/2 Withdrawn
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Phase 1/2 Withdrawn
NeoPSMA
Phase 1/2 Withdrawn
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1/2 Withdrawn
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1/2 Withdrawn
B-ALL
Phase 1/2 Withdrawn
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1/2 Withdrawn
FORTIFIDE
Phase 1/2 Withdrawn
MK-9999-01B
Phase 1/2 Withdrawn
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Phase 1/2 Withdrawn
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Phase 1/2 Withdrawn
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1/2 Withdrawn
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Phase 1/2 Withdrawn
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1/2 Withdrawn
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1/2 Withdrawn
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1/2 Withdrawn
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1/2 Withdrawn
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Phase 1/2 Withdrawn
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
Phase 1/2 Withdrawn
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Phase 1/2 Withdrawn
MANHATTAN
Phase 1/2 Withdrawn
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Phase 1/2 Withdrawn
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Phase 1/2 Withdrawn
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
Phase 1/2 Withdrawn
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Phase 1/2 Withdrawn
CheckMate 79X
Phase 1/2 Withdrawn
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Phase 1/2 Withdrawn
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Phase 1/2 Withdrawn
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Phase 1/2 Withdrawn
ARIA
Phase 1/2 Withdrawn
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Phase 1/2 Withdrawn
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Phase 1/2 Withdrawn
NEWEL
Phase 1/2 Withdrawn
CYNK001GBM02
Phase 1/2 Withdrawn
SLAM
Phase 1/2 Withdrawn
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Phase 1/2 Withdrawn
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Phase 1/2 Withdrawn
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Phase 1/2 Withdrawn
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Phase 1/2 Withdrawn
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Phase 1/2 Withdrawn
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Phase 1/2 Withdrawn
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Phase 1/2 Withdrawn
Study of SM-88 in Advanced Cancers
Phase 1/2 Withdrawn
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Phase 1/2 Withdrawn
HERKULES-4
Phase 1/2 Withdrawn
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Phase 1/2 Withdrawn
RENACOL
Phase 1/2 Withdrawn